Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract.

To investigate the association between elevated intraocular pressure (IOP) and accelerated cataract formation in patients treated with intravitreal triamcinolone.
Analysis of longitudinal data from a randomized, double-masked, placebo-controlled trial of intravitreal triamcinolone for age-related macular degeneration (the Intravitreal Triamcinolone Study).
Patients with phakic eyes who participated in a randomized clinical trial of intravitreal triamcinolone for age-related macular degeneration were studied. There were 57 phakic eyes in the treatment group and 54 phakic eyes in the control group. One eye per patient was studied.
Four milligrams of intravitreal triamcinolone or 1 ml subconjunctival saline.
Intraocular pressure rise of at least 5 mmHg (IOP responders) and progression of posterior subcapsular cataract by 2 or more grades using photographic standards from the Age Related Eye Disease Study.
Progression of posterior subcapsular cataract (PSC) by 2 or more grades in the treatment group was significantly higher among 16 IOP responders (51% after 2 years) than among 37 nonresponders (3%; P<0.0001, log-rank test). There was no significant progression of PSC in the placebo group or the opposite eye of the treatment group. Progression of cortical cataracts also was significantly higher among responders than nonresponders (15% vs. 3%; P = 0.015, log-rank test). The progression of nuclear cataracts (13% vs. 3%) was not significantly different between IOP responders and nonresponders (P = 0.3, log-rank test).
Although steroid-related cataracts are unlikely to develop in eyes that do not experience elevated IOP after intravitreal triamcinolone, those eyes that do also have a very high risk of rapidly experiencing posterior subcapsular lens opacification. This strong association suggests that the mechanism responsible for the development of steroid-induced PSC cataract and raised IOP may be similar.
AuthorsMark C Gillies, Maciek Kuzniarz, Jamie Craig, Matthew Ball, Wei Luo, Judy M Simpson
JournalOphthalmology (Ophthalmology) Vol. 112 Issue 1 Pg. 139-43 (Jan 2005) ISSN: 1549-4713 [Electronic] United States
PMID15629834 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Glucocorticoids
  • Triamcinolone Acetonide
  • Aged
  • Cataract (chemically induced)
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Glucocorticoids (adverse effects)
  • Humans
  • Injections
  • Intraocular Pressure (drug effects)
  • Lens, Crystalline (drug effects, physiology)
  • Macular Degeneration (drug therapy)
  • Male
  • Tonometry, Ocular
  • Triamcinolone Acetonide (adverse effects)
  • Vitreous Body

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: